No image published for this recall
Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis
Official notice
21 Aug 2025
Last checked
21 Aug 2025
An official Health Canada notice concerns Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis. Health Canada is warning patients that they may experience anaphylactic reactions after receiving glatiramer acetate, which is used to treat relapsing-remitting multiple sclerosis. These anaphylactic reactions can be fatal and may occur at any point during treatment, from as soon as the first dose to months or even years after starting therapy. Anaphylactic reaction symptoms generally appear within one hour of injection and may include: Sudden shortness of breath, wheezing, or difficulty breathing Swelling of the eyelids, face, lips, mouth, tongue, or throat Uncontrolled shaking Fainting or dizziness Trouble swallowing or speaking Widespread rash, hives Collapse Health Canada confirmed this new safety risk following a review of all available data, including 11 Canadian cases of anaphylactic reactions from Copaxone and three additional cases from other glatiramer acetate products. While there have been no fatal cases reported in Canada, some cases required treatment with epinephrine and other appropriate medical interventions. There have been fatal cases reported internationally. Health Canada has informed healthcare professionals, including neurologists, emergency room physicians and staff, nurses, and pharmacists about this new safety risk. The manufacturer for Copaxone has updated its Canadian product labelling to include this risk, and Health Canada is working with the manufacturers of other glatiramer acetate products — including Glatect and Mylan glatiramer acetate injection — to update their respective labelling. Published 2025-08-21.
What to do now
If you experience anaphylactic reaction symptoms, stop taking glatiramer acetate and seek immediate medical help by calling 9-1-1. Do not restart taking glatiramer acetate if you have experienced anaphylaxis unless your healthcare provider has identified another clear cause for the anaphylaxis. Report any health product-related side effects to Health Canada. What healthcare professionals should do Inform patients and/or caregivers of the signs and symptoms of anaphylactic reactions, which may overlap with those of an immediate post-injection reaction. Instruct patients to seek immediate emergency medical care in the event of an anaphylactic reaction. Instruct patients to discontinue treatment with glatiramer acetate if they have an anaphylactic reaction. Do not restart the medicine unless there is another clear reason the patient experienced an anaphylactic reaction.
Recall number
77939
Official notice
2025-08-21
The hazard
The hazard
Health Canada is warning patients that they may experience anaphylactic reactions after receiving glatiramer acetate, which is used to treat relapsing-remitting multiple sclerosis. These anaphylactic reactions can be fatal and may occur at any point during treatment, from as soon as the first dose to months or even years after starting therapy. Anaphylactic reaction symptoms generally appear within one hour of injection and may include: Sudden shortness of breath, wheezing, or difficulty breathing Swelling of the eyelids, face, lips, mouth, tongue, or throat Uncontrolled shaking Fainting or dizziness Trouble swallowing or speaking Widespread rash, hives Collapse Health Canada confirmed this new safety risk following a review of all available data, including 11 Canadian cases of anaphylactic reactions from Copaxone and three additional cases from other glatiramer acetate products. While there have been no fatal cases reported in Canada, some cases required treatment with epinephrine and other appropriate medical interventions. There have been fatal cases reported internationally. Health Canada has informed healthcare professionals, including neurologists, emergency room physicians and staff, nurses, and pharmacists about this new safety risk. The manufacturer for Copaxone has updated its Canadian product labelling to include this risk, and Health Canada is working with the manufacturers of other glatiramer acetate products — including Glatect and Mylan glatiramer acetate injection — to update their respective labelling.
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Follow the official notice if they match.
Recall Numbers
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsAffected products
Affected products
Product 1
Product 2
Product 3
Product 4
Product 5
Risk / hazard
Where it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Company & contacts
Company & contacts
Brand: RAM, Glatiramer Acetate.
Source & status
Source & status
Source
Tier
Category
App estimate
Recall details
Recall details
Recall number
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeWeekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 21 Aug 2025. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.
